• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Glenmark Pharmaceuticals Ltd.
    09 Sep 2025, 11:49AM
    2116.30
    3.14%
    Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie
    Business Line
    The Mumbai-based drugmaker had in July announced this deal on itsdrug candidate that was in early Phase-I clinical trials and had shown promising outcomes in patients with relapsed / refractory multiple myeloma
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
    Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn
    Business Standard | 09 Sep 2025, 10:50AM
    logo
    Morepen Laboratories Ltd.
    09 Sep 2025, 10:28AM
    Forms JV
    51.22
    4.34%
    Morepen Laboratories shares jump 6%; what's driving buying interest?
    Business Standard
    Morepen Laboratories shares jumped 5.7 per cent, after the company arm Morepen Medipath executed a joint venture (JV) agreement with Bimedical FZE, a UAE based entity
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 57 to 49 in Jun 2025 qtr
    logo
    Amanta Healthcare Ltd.
    09 Sep 2025, 07:28AM
    IPO Listing 10-year high
    141.75
    12.50%
    Amanta Healthcare Shares To List Today: Here's What Latest GMP Signals Ahead Of Listing
    Amanta Healthcare Shares To List Today: Here's What Latest GMP Signals Ahead Of Listing
    NDTV Profit
    Ahead of its debut on the stock market, the shares of Amanta Healthcare are trading at a premium in the grey market, indicating positive gains for the investors.
    Copy LinkShare onShare on Share on Share on
    No SMAs available
    logo
    Strides Pharma Science Ltd.
    08 Sep 2025, 10:14PM
    878.25
    -0.36%
    Strides enters into product partnership with Kenox for nasal spray
    Business Standard
    Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have...
    Copy LinkShare onShare on Share on Share on
    Strides Pharma Science Ltd. is trading above all available SMAs
    Strides Pharma inks collaboration with Kenox for nasal spray portfolio in the US
    Business Line | 08 Sep 2025, 08:38PM
    logo
    Mankind Pharma Ltd.
    08 Sep 2025, 03:44PM
    CDSCO Approval
    2589.30
    0.38%
    Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug
    Business Standard
    Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. is trading above all available SMAs
    CDSCO clears Mankind's Phase 1 trial for autoimmune disorder molecule
    Business Standard | 08 Sep 2025, 12:50PM
    logo
    AstraZeneca Pharma India Ltd.
    07 Sep 2025
    9100.50
    0.61%
    AstraZeneca's lung cancer combination boosted survival in key study
    Business Standard
    The combination helped patients with a specific type of advanced non-small cell lung cancer live for 47.5 months at the median, the longest survival benefit ever reported
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. has gained 32.19% in the last 1 Year
    logo
    AstraZeneca Pharma India Ltd.
    06 Sep 2025
    9100.50
    0.61%
    AstraZeneca to invest 176 cr to expand GITC in Chennai
    Business Line
    The new investment, third in the past two years in India, will expand the GITC to strengthen its position as a leader in healthcare innovation both globally and in the country
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    Ashok Leyland to invest 7,500 cr in TN, AstraZeneca to expand GITC
    Business Standard | 06 Sep 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    05 Sep 2025
    1591.70
    0.68%
    Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead
    Business Standard
    The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    logo
    Cipla Ltd.
    05 Sep 2025
    1551.60
    0.67%
    Cipla launches Huena, India's first non-antibiotic drug to fight UTI
    Business Standard
    Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    logo
    Torrent Pharmaceuticals Ltd.
    04 Sep 2025
    3643.30
    0.84%
    Torrent Pharma Announces Open Offer To Acquire Rs 6,843-Crore Stake In JB Chemicals
    Torrent Pharma Announces Open Offer To Acquire Rs 6,843-Crore Stake In JB Chemicals
    NDTV Profit
    Once the deal is finalised, Torrent Pharmaceuticals will become India's second most valued pharma company.
    Copy LinkShare onShare on Share on Share on
    Torrent Pharmaceuticals Ltd. is trading above all available SMAs
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd